Marie L Pancera

US Patent:

20190112340, Apr 18, 2019

Filed:

Mar 29, 2017

Appl. No.:

16/089993

Inventors:

- Bethesda MD, US
Barney Graham - Rockville MD, US
John Mascola - Rockville MD, US
Li Ou - Potomac MD, US
Aliaksandr Druz - Germantown MD, US
Man Chen - Bethesda MD, US
Wing-Pui Kong - Germantown MD, US
Ivelin Stefanov Georgiev - Nashville TN, US
Emily Rundlet - New York NY, US
Michael Gordon Joyce - Washington DC, US
Yaroslav Tsybovsky - Frederick MD, US
Paul Thomas - Washington DC, US
Marie Pancera - Seattle WA, US
Mallika Sastry - Rockville MD, US
Cinque Soto - Nashville TN, US
Joseph Van Galen - North Wales PA, US
Guillaume Stewart-Jones - Bethesda MD, US
Yongping Yang - Potomac MD, US
Baoshan Zhang - Bethesda MD, US
Ulrich Baxa - Frederick MD, US

Assignee:

The United States of America, as represented by the Secretary, Department of Health and Human - Bethesda MD

International Classification:

C07K 14/005
A61P 31/14
A61P 37/04

Abstract:

Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.

US Patent:

20180319846, Nov 8, 2018

Filed:

Jul 2, 2018

Appl. No.:

16/025858

Inventors:

- Bethesda MD, US
Barney S. Graham - Rockville MD, US
Jason S. McLellan - Austin TX, US
Jeffrey Boyington - Clarksburg MD, US
Lei Chen - Rockville MD, US
Man Chen - Bethesda MD, US
Ivelin Stefanov Georgiev - Nashville TN, US
Jason Gorman - Washington DC, US
Michael Gordon Joyce - Washington DC, US
Masaru Kanekiyo - Chevy Chase MD, US
Gilad Ofek - Gaithersburg MD, US
Marie Pancera - Seattle WA, US
Mallika Sastry - Rockville MD, US
Cinque Soto - Rockville MD, US
Sanjay Srivatsan - Lilburn GA, US
Guillaume Stewart-Jones - Bethesda MD, US
Yongping Yang - Potomac MD, US
Baoshan Zhang - Bethesda MD, US
Tongqing Zhou - Boyds MD, US

Assignee:

The United States of America,as represented by the Secretary,Department of Helath and Human Services - Bethesda MD

International Classification:

C07K 14/005
A61K 39/155
C12N 7/00
A61K 39/12
G01N 33/564
A61K 39/00

Abstract:

Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.

US Patent:

20170233441, Aug 17, 2017

Filed:

Sep 4, 2015

Appl. No.:

15/508885

Inventors:

- Bethesda MD, US
Marie Pancera - Seattle WA, US
Tongqing Zhou - Boyds MD, US
Ivelin Georgiev - Nashville TN, US
Michael Gordon Joyce - Bethesda MD, US
Priyamvada Acharya - Fort Lee NJ, US
Jason Gorman - Washington DC, US
Yongping Yang - Potomac MD, US
Aliaksandr Druz - Germantown MD, US
Guillaume Stewart-Jones - Bethesda MD, US
Rita Chen - Bethesda MD, US
Ulrich Baxa - Frederick MD, US
John Mascola - Rockville MD, US
Rebecca Lynch - Washington DC, US
Baoshan Zhang - Bethesda MD, US
Cheng Cheng - Rockville MD, US

Assignee:

The United States of America, as represented by the Secretary, Department of Health and Human Serv - Bethesda MD

International Classification:

C07K 14/435
A61K 39/21
G01N 33/569
C07K 16/10

Abstract:

HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.

US Patent:

20160046675, Feb 18, 2016

Filed:

Mar 13, 2014

Appl. No.:

14/776651

Inventors:

- Bethesda MD, US
Barney S. Graham - Rockville MD, US
Jason S. McLellan - Norwich VT, US
Jeffrey Boyington - Clarksburg MD, US
Lei Chen - Rockville MD, US
Man Chen - Bethesda MD, US
Ivelin Stefanov Georgiev - Gaithersburg MD, US
Jason Gorman - Washington DC, US
Michael Gordon Joyce - Washington DC, US
Masaru Kanekiyo - Chevy Chase MD, US
Gilad Ofek - Gaithersburg MD, US
Marie Pancera - McLean VA, US
Mallika Sastry - Rockville MD, US
Cinque Soto - Rockville MD, US
Sanjay Srivatsan - Lilburn GA, US
Guillaume Stewart-Jones - Bethesda MD, US
Yongping Yang - Potomac MD, US
Baoshan Zhang - Bethesda MD, US
Tongqing Zhou - Boyds MD, US

Assignee:

The USA, as represented by the Secretary, Departm- ent of Health and Human Service - Bethesda MD

International Classification:

C07K 14/005
A61K 39/155
G01N 33/564
C12N 7/00

Abstract:

Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.

US Patent:

20140342407, Nov 20, 2014

Filed:

Aug 4, 2014

Appl. No.:

14/450773

Inventors:

- Bethesda MD, US
Jinghe Huang - Bethesda MD, US
Leo Laub - Richmond VA, US
John Mascola - Rockville MD, US
Nancy Longo - Kensington MD, US
Nicole Doria-Rose - Kensington MD, US
Marie Pancera - McLean VA, US

International Classification:

C07K 16/10
G01N 33/569
C07K 16/00

US Classification:

435 696, 506 9, 506 2

Abstract:

Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.

US Patent:

20140271699, Sep 18, 2014

Filed:

Mar 12, 2014

Appl. No.:

14/207372

Inventors:

- Bethesda MD, US
Barney Graham - Rockville MD, US
Jason McLellan - Hanover NH, US
Jeffrey Boyington - Clarksburg MD, US
Ivelin Stefanov Georgiev - Gaithersburg MD, US
Michael Gordon Joyce - Washington DC, US
Masaru Kanekiyo - Chevy Chase MD, US
Marie Pancera - Washington DC, US
Cinque Soto - Rockville MD, US
Sanjay Srivatsan - Lilburn GA, US
Baoshan Zhang - Bethesda MD, US

International Classification:

C07K 14/005

US Classification:

4241871, 530350, 536 2372, 4353201, 4352523, 43525411, 4352542, 435348, 435419, 435325, 435366, 43525233, 43525231, 43525421, 435369

Abstract:

Disclosed are immunogens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the immunogens and methods of producing the immunogens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the immunogen to the subject.